Literature DB >> 19773448

TrkBT1 induces liver metastasis of pancreatic cancer cells by sequestering Rho GDP dissociation inhibitor and promoting RhoA activation.

Zhongkui Li1, Zhe Chang, Lucia J Chiao, Ya'an Kang, Qianghua Xia, Cihui Zhu, Jason B Fleming, Douglas B Evans, Paul J Chiao.   

Abstract

Many genetic and molecular alterations, such as K-ras mutation and NF-kappaB activation, have been identified in pancreatic cancer. However, the mechanisms by which pancreatic cancer metastasizes still remain to be determined. Although we previously showed that the tropomyosin-related kinase B (TrkB) was significantly correlated with the development of liver metastasis, its function in pancreatic cancer metastasis remained unresolved. In the present study, we showed that overexpressed TrkB is an alternatively spliced transcript variant of TrkB (TrkBT1) with a unique COOH-terminal 12-amino acid sequence and is mainly localized in the cytoplasm. Our results showed that overexpression of Flag-tagged TrkBT1 but not a Flag-tagged TrkBT1 COOH-terminal deletion mutant (Flag-TrkBT1DeltaC) in nonmetastatic pancreatic cancer cells enhanced cell proliferation, promoted formation of colonies in soft agar, stimulated tumor cell invasion, and induced liver metastasis in an orthotopic xenograft mouse model of pancreatic cancer. TrkBT1 interacted with Rho GDP dissociation inhibitor (GDI) in vivo, but Flag-TrkBT1DeltaC did not. Furthermore, overexpression of Flag-TrkBT1 and knockdown of RhoGDI expression by RhoGDI short hairpin RNAs promoted RhoA activation, but Flag-TrkBT1DeltaC overexpression did not. Therefore, our results showed that TrkBT1 overexpression induces liver metastasis of pancreatic cancer and uncovered a unique signaling mechanism by which TrkBT1 sequesters GDI and activates RhoA signaling.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19773448      PMCID: PMC3087630          DOI: 10.1158/0008-5472.CAN-08-4002

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  35 in total

1.  Correlation between RhoA overexpression and tumour progression in esophageal squamous cell carcinoma.

Authors:  A Faried; M Nakajima; M Sohda; T Miyazaki; H Kato; H Kuwano
Journal:  Eur J Surg Oncol       Date:  2005-05       Impact factor: 4.424

Review 2.  Advances in the diagnosis and treatment of adenocarcinoma of the pancreas.

Authors:  D B Evans; J E Lee; P W Pisters; C Charnsangavej; L M Ellis; P J Chiao; R Lenzi; J L Abbruzzese
Journal:  Cancer Treat Res       Date:  1997

3.  Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy.

Authors:  Erlinda E Embuscado; Daniel Laheru; Francesca Ricci; Ki Jung Yun; Sten de Boom Witzel; Allison Seigel; Katie Flickinger; Manuel Hidalgo; G Steven Bova; Christine A Iacobuzio-Donahue
Journal:  Cancer Biol Ther       Date:  2005-05-12       Impact factor: 4.742

4.  A truncated tropomyosin-related kinase B receptor, T1, regulates glial cell morphology via Rho GDP dissociation inhibitor 1.

Authors:  Koji Ohira; Haruko Kumanogoh; Yoshinori Sahara; Koichi J Homma; Hirohisa Hirai; Shun Nakamura; Motoharu Hayashi
Journal:  J Neurosci       Date:  2005-02-09       Impact factor: 6.167

5.  Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells.

Authors:  Guido M Sclabas; Shuichi Fujioka; Christian Schmidt; Zhongkui Li; Wayne A I Frederick; Wentao Yang; Kenji Yokoi; Douglas B Evans; James L Abbruzzese; Kenneth R Hess; Wei Zhang; Isaiah J Fidler; Paul J Chiao
Journal:  Clin Cancer Res       Date:  2005-01-15       Impact factor: 12.531

6.  Autocrine motility factor signaling enhances pancreatic cancer metastasis.

Authors:  Soichi Tsutsumi; Takashi Yanagawa; Tatsuo Shimura; Hiroyuki Kuwano; Avraham Raz
Journal:  Clin Cancer Res       Date:  2004-11-15       Impact factor: 12.531

7.  Heterogeneity of potential for hematogenous metastasis in a human pancreatic carcinoma.

Authors:  M P Vezeridis; P A Meitner; L M Tibbetts; C M Doremus; G Tzanakakis; P Calabresi
Journal:  J Surg Res       Date:  1990-01       Impact factor: 2.192

8.  Neurotrophin gene expression by cell lines derived from human gliomas.

Authors:  W Hamel; M Westphal; E Szönyi; E Escandón; K Nikolics
Journal:  J Neurosci Res       Date:  1993-02-01       Impact factor: 4.164

9.  A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis.

Authors:  Scott Valastyan; Ferenc Reinhardt; Nathan Benaich; Diana Calogrias; Attila M Szász; Zhigang C Wang; Jane E Brock; Andrea L Richardson; Robert A Weinberg
Journal:  Cell       Date:  2009-06-12       Impact factor: 41.582

10.  Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4.

Authors:  Federica Marchesi; Paolo Monti; Biagio Eugenio Leone; Alessandro Zerbi; Annunciata Vecchi; Lorenzo Piemonti; Alberto Mantovani; Paola Allavena
Journal:  Cancer Res       Date:  2004-11-15       Impact factor: 12.701

View more
  24 in total

1.  Rho kinase signaling pathways during stretch in primary alveolar epithelia.

Authors:  Brian C DiPaolo; Susan S Margulies
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-01-27       Impact factor: 5.464

Review 2.  Cdc42 in oncogenic transformation, invasion, and tumorigenesis.

Authors:  Kristy Stengel; Yi Zheng
Journal:  Cell Signal       Date:  2011-04-16       Impact factor: 4.315

3.  Bif-1 promotes tumor cell migration and metastasis via Cdc42 expression and activity.

Authors:  Cunzhen Zhang; Fenghua Liu; Haiyang Chen; Nan Li; Zaili Luo; Weixing Guo; Dandan Huang; Shanhua Tang; Honggang Wang; Shuqun Cheng; Zhong Li; Hongyang Wang
Journal:  Clin Exp Metastasis       Date:  2016-10-11       Impact factor: 5.150

4.  Geranylgeranyltransferase I promotes human glioma cell growth through Rac1 membrane association and activation.

Authors:  Xiuping Zhou; Jinming Qian; Lei Hua; Qiong Shi; Zhi Liu; Yinfu Xu; Ben Sang; Jianbing Mo; Rutong Yu
Journal:  J Mol Neurosci       Date:  2012-10-17       Impact factor: 3.444

5.  Eukaryotic Translation Initiation Factor 5A (EIF5A) Regulates Pancreatic Cancer Metastasis by Modulating RhoA and Rho-associated Kinase (ROCK) Protein Expression Levels.

Authors:  Ken Fujimura; Sunkyu Choi; Meghan Wyse; Jan Strnadel; Tracy Wright; Richard Klemke
Journal:  J Biol Chem       Date:  2015-10-19       Impact factor: 5.157

6.  Cyclic AMP regulates the migration and invasion potential of human pancreatic cancer cells.

Authors:  Noah P Zimmerman; Ishan Roy; Andrew D Hauser; Jessica M Wilson; Carol L Williams; Michael B Dwinell
Journal:  Mol Carcinog       Date:  2013-09-24       Impact factor: 4.784

7.  Role and relevance of TrkB mutations and expression in non-small cell lung cancer.

Authors:  Taishi Harada; Yasushi Yatabe; Masafumi Takeshita; Takaomi Koga; Tokujiro Yano; Yisong Wang; Giuseppe Giaccone
Journal:  Clin Cancer Res       Date:  2011-01-17       Impact factor: 12.531

8.  The Correlation Between RhoA Expression and Clinicopathological Characteristics in Gastric Cancer Patients After Curative Surgery.

Authors:  Kuo-Hung Huang; Yuan-Tzu Lan; Ming-Huang Chen; Yee Chao; Su-Shun Lo; Anna Fen-Yau Li; Chew-Wun Wu; Shih-Hwa Chiou; Muh-Hwa Yang; Yi-Ming Shyr; Wen-Liang Fang
Journal:  World J Surg       Date:  2015-09       Impact factor: 3.352

9.  Two-dimensional culture of human pancreatic adenocarcinoma cells results in an irreversible transition from epithelial to mesenchymal phenotype.

Authors:  Ya'an Kang; Ran Zhang; Rei Suzuki; Shao-qiang Li; David Roife; Mark J Truty; Deyali Chatterjee; Ryan M Thomas; James Cardwell; Yu Wang; Huamin Wang; Matthew H Katz; Jason B Fleming
Journal:  Lab Invest       Date:  2014-12-08       Impact factor: 5.662

Review 10.  Tropomyosin-related kinase B/brain derived-neurotrophic factor signaling pathway as a potential therapeutic target for colorectal cancer.

Authors:  Hussein Akil; Aurélie Perraud; Marie-Odile Jauberteau; Muriel Mathonnet
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.